

Bibliography

Abdel-Wahab, O., Adli, M., LaFave, L.M., Gao, J., Hricik, T., Shih, A.H., Pandey, S., Patel, J.P., Chung, Y.R., Koche, R., *et al.* (2012). ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. *Cancer cell* 22, 180-193.

Abdi, J., Chen, G., and Chang, H. (2013). Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. *Oncotarget* 4, 2186-2207.

Acuna-Hidalgo, R., Sengul, H., Steehouwer, M., van de Vorst, M., Vermeulen, S.H., Kiemeneij, L., Veltman, J.A., Gilissen, C., and Hoischen, A. (2017). Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. *American journal of human genetics*.

Adams, P.D., Jasper, H., and Rudolph, K.L. (2015). Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. *Cell stem cell* 16, 601-612.

Agathocleous, M., Meacham, C.E., Burgess, R.J., Piskounova, E., Zhao, Z., Crane, G.M., Cowin, B.L., Bruner, E., Murphy, M.M., Chen, W., *et al.* (2017). Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. *Nature advance online publication*.

Akbari, M.R., Lepage, P., Rosen, B., McLaughlin, J., Risch, H., Minden, M., and Narod, S.A. (2014). PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. *Journal of the National Cancer Institute* 106, djt323.

Alexandrov, L., Kim, J., Haradhvala, N.J., Huang, M.N., Ng, A.W.T., Boot, A., Covington, K.R., Gordenin, D.A., Bergstrom, E., Lopez-Bigas, N., *et al.* (2018). The Repertoire of Mutational Signatures in Human Cancer. 322859.

Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.-L., *et al.* (2013). Signatures of mutational processes in human cancer. *Nature* 500, 415-421.

Altorki, N.K., Markowitz, G.J., Gao, D., Port, J.L., Saxena, A., Stiles, B., McGraw, T., and Mittal, V. (2019). The lung microenvironment: an important regulator of tumour growth and metastasis. *Nature reviews Cancer* 19, 9-31.

Amoyel, M., and Bach, E.A. (2014). Cell competition: how to eliminate your neighbours. *Development (Cambridge, England)* 141, 988-1000.

Andersen, S.L., Sebastiani, P., Dworkis, D.A., Feldman, L., and Perls, T.T. (2012). Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. *J Gerontol A Biol Sci Med Sci* 67, 395-405.

Anderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Colman, S.M., Kempinski, H., Moorman, A.V., Titley, I., Swansbury, J., *et al.* (2011). Genetic variegation of clonal architecture and propagating cells in leukaemia. *Nature* 469, 356-361.

Andersson, A.K., Ma, J., Wang, J., Chen, X., Gedman, A.L., Dang, J., Nakitandwe, J., Holmfeldt, L., Parker, M., Easton, J., *et al.* (2015). The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. *Nature genetics* 47, 330-337.

Antoniou, A.C., Goldgar, D.E., Andrieu, N., Chang-Claude, J., Brohet, R., Rookus, M.A., and Easton, D.F. (2005). A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genetic epidemiology* 29, 1-11.

Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M., and Vardiman, J.W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 127, 2391-2405.

Armitage, P., and Doll, R. (1954). The age distribution of cancer and a multi-stage theory of carcinogenesis. *British journal of cancer* 8, 1-12.

Armstrong, G.T., Chen, Y., Yasui, Y., Leisenring, W., Gibson, T.M., Mertens, A.C., Stovall, M., Oeffinger, K.C., Bhatia, S., Krull, K.R., *et al.* (2016). Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. *The New England journal of medicine* 374, 833-842.

Artomov, M., Rivas, M.A., Genovese, G., and Daly, M.J. (2017). Mosaic mutations in blood DNA sequence are associated with solid tumor cancers. *NPJ genomic medicine* 2, 22.

Astle, W.J., Elding, H., Jiang, T., Allen, D., Ruklisa, D., Mann, A.L., Mead, D., Bouman, H., Riveros-Mckay, F., Kostadima, M.A., *et al.* (2016). The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell* 167, 1415-1429.e1419.

Austin, H., Delzell, E., and Cole, P. (1988). Benzene and leukemia. A review of the literature and a risk assessment. *American journal of epidemiology* 127, 419-439.

Avery, O.T., Macleod, C.M., and McCarty, M. (1944). Studies on the Chemical Nature of the Substance Inducing Transformation of Pneumococcal Types : Induction of Transformation by a Desoxyribonucleic Acid Fraction Isolated from Pneumococcus Type Iii. *The Journal of experimental medicine* 79, 137-158.

Bahr, C., von Paleske, L., Uslu, V.V., Remeseiro, S., Takayama, N., Ng, S.W., Murison, A., Langenfeld, K., Petretich, M., Scognamiglio, R., *et al.* (2018). A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. *Nature*.

Baker, N.E., and Li, W. (2008). Cell competition and its possible relation to cancer. *Cancer research* 68, 5505-5507.

Balicer, R.D., and Afek, A. (2017). Digital health nation: Israel's global big data innovation hub. *Lancet (London, England)* 389, 2451-2453.

- Ballinger, M.L., Goode, D.L., Ray-Coquard, I., James, P.A., Mitchell, G., Niedermayr, E., Puri, A., Schiffman, J.D., Dite, G.S., Cipponi, A., *et al.* (2016). Monogenic and polygenic determinants of sarcoma risk: an international genetic study. *The Lancet Oncology* *17*, 1261-1271.
- Bateman, C.M., Alpar, D., Ford, A.M., Colman, S.M., Wren, D., Morgan, M., Kearney, L., and Greaves, M. (2015). Evolutionary trajectories of hyperdiploid ALL in monozygotic twins. *Leukemia* *29*, 58-65.
- Behjati, S., Gundem, G., Wedge, D.C., Roberts, N.D., Tarpey, P.S., Cooke, S.L., Van Loo, P., Alexandrov, L.B., Ramakrishna, M., Davies, H., *et al.* (2016). Mutational signatures of ionizing radiation in second malignancies. *Nature communications* *7*, 12605.
- Behjati, S., Huch, M., van Boxtel, R., Karthaus, W., Wedge, D.C., Tamuri, A.U., Martincorena, I., Petljak, M., Alexandrov, L.B., Gundem, G., *et al.* (2014). Genome sequencing of normal cells reveals developmental lineages and mutational processes. *Nature* *513*, 422-425.
- Behjati, S., Lindsay, S., Teichmann, S.A., and Haniffa, M. (2018). Mapping human development at single-cell resolution. *Development (Cambridge, England)* *145*.
- Bejar, R. (2017). CHIP, ICUS, CCUS and other four-letter words. *Leukemia* *31*, 1869-1871.
- Benn, M., Tybjaerg-Hansen, A., Stender, S., Frikke-Schmidt, R., and Nordestgaard, B.G. (2011). Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. *Journal of the National Cancer Institute* *103*, 508-519.
- Bhakta, N., Liu, Q., Ness, K.K., Baassiri, M., Eissa, H., Yeo, F., Chemaitilly, W., Ehrhardt, M.J., Bass, J., Bishop, M.W., *et al.* (2017). The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet (London, England)* *390*, 2569-2582.
- Bhatia, S. (2013). Therapy-related myelodysplasia and acute myeloid leukemia. *Seminars in oncology* *40*, 666-675.
- Bhatia, S., Krailo, M.D., Chen, Z., Burden, L., Askin, F.B., Dickman, P.S., Grier, H.E., Link, M.P., Meyers, P.A., Perlman, E.J., *et al.* (2007). Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. *Blood* *109*, 46-51.
- Blanco, J.G., Dervieux, T., Edick, M.J., Mehta, P.K., Rubnitz, J.E., Shurtleff, S., Raimondi, S.C., Behm, F.G., Pui, C.H., and Relling, M.V. (2001). Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America* *98*, 10338-10343.
- Blokzijl, F., de Ligt, J., Jager, M., Sasselli, V., Roerink, S., Sasaki, N., Huch, M., Boymans, S., Kuijk, E., Prins, P., *et al.* (2016). Tissue-specific mutation accumulation in human adult stem cells during life. *Nature* *538*, 260-264.

- Bolli, N., Avet-Loiseau, H., Wedge, D.C., Van Loo, P., Alexandrov, L.B., Martincorena, I., Dawson, K.J., Iorio, F., Nik-Zainal, S., Bignell, G.R., *et al.* (2014). Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nature communications* 5, 2997.
- Bolton, K.L., Gillis, N.K., Coombs, C.C., Takahashi, K., Zehir, A., Bejar, R., Garcia-Manero, G., Futreal, A., Jensen, B.C., Diaz, L.A., Jr., *et al.* (2019). Managing Clonal Hematopoiesis in Patients With Solid Tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 37, 7-11.
- Bondar, T., and Medzhitov, R. (2010). p53-mediated hematopoietic stem and progenitor cell competition. *Cell stem cell* 6, 309-322.
- Bonnefond, A., Skrobek, B., Lobbens, S., Eury, E., Thuillier, D., Cauchi, S., Lantieri, O., Balkau, B., Riboli, E., Marre, M., *et al.* (2013). Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. *Nature genetics* 45, 1040-1043.
- Bowman, R.L., Busque, L., and Levine, R.L. (2018). Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. *Cell stem cell* 22, 157-170.
- Brunetti, L., Gundry, M.C., and Goodell, M.A. (2017). DNMT3A in Leukemia. *Cold Spring Harbor perspectives in medicine* 7.
- Buels, R., Yao, E., Diesh, C.M., Hayes, R.D., Munoz-Torres, M., Helt, G., Goodstein, D.M., Elsik, C.G., Lewis, S.E., Stein, L., *et al.* (2016). JBrowse: a dynamic web platform for genome visualization and analysis. *Genome biology* 17, 66.
- Buscarlet, M., Provost, S., Feroz Zada, Y., Barhdadi, A., Bourgoin, V., Lepine, G., Mollica, L., Szuber, N., Dube, M.P., and Busque, L. (2017). DNMT3A and TET2 dominate clonal hematopoiesis, demonstrate benign phenotypes and different genetic predisposition. *Blood*.
- Busque, L., Buscarlet, M., Mollica, L., and Levine, R.L. (2018). Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. *Stem cells (Dayton, Ohio)* 36, 1287-1294.
- Busque, L., Mio, R., Mattioli, J., Brais, E., Blais, N., Lalonde, Y., Maragh, M., and Gilliland, D.G. (1996). Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. *Blood* 88, 59-65.
- Busque, L., Patel, J.P., Figueroa, M.E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., *et al.* (2012). Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nature genetics* 44, 1179-1181.
- Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., *et al.* (2018). The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203-209.
- Cairns, J. (1975). Mutation selection and the natural history of cancer. *Nature* 255, 197-200.

Campbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D., Stebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.L., *et al.* (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* *467*, 1109-1113.

Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H., and Jaffe, E.S. (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood* *117*, 5019-5032.

Carrelha, J., Meng, Y., Kettyle, L.M., Luis, T.C., Norfo, R., Alcolea, V., Boukarabila, H., Grasso, F., Gambardella, A., Grover, A., *et al.* (2018). Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. *Nature* *554*, 106-111.

Carver, J.R., Shapiro, C.L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K.S., Hagerty, K.L., Somerfield, M.R., and Vaughn, D.J. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* *25*, 3991-4008.

Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., *et al.* (2011). Dnmt3a is essential for hematopoietic stem cell differentiation. *Nature genetics* *44*, 23-31.

Chang, W., Brohl, A.S., Patidar, R., Sindiri, S., Shern, J.F., Wei, J.S., Song, Y.K., Yohe, M.E., Gryder, B., Zhang, S., *et al.* (2016). MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. *Clinical cancer research : an official journal of the American Association for Cancer Research* *22*, 3810-3820.

Chapuy, B., Stewart, C., Dunford, A.J., Kim, J., Kamburov, A., Redd, R.A., Lawrence, M.S., Roemer, M.G.M., Li, A.J., Ziepert, M., *et al.* (2018). Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nature medicine* *24*, 679-690.

Chen, J., Kao, Y.R., Sun, D., Todorova, T.I., Reynolds, D., Narayanagari, S.R., Montagna, C., Will, B., Verma, A., and Steidl, A.U. (2018). Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. *Nature medicine*.

Churpek, J.E., Marquez, R., Neistadt, B., Claussen, K., Lee, M.K., Churpek, M.M., Huo, D., Weiner, H., Bannerjee, M., Godley, L.A., *et al.* (2016). Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. *Cancer* *122*, 304-311.

Ciccarelli, F.D. (2019). Mutations differ in normal and cancer cells of the oesophagus. *Nature* *565*, 301-303.

Cimmino, L., Dolgalev, I., Wang, Y., Yoshimi, A., Martin, G.H., Wang, J., Ng, V., Xia, B., Witkowski, M.T., Mitchell-Flack, M., *et al.* (2017). Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. *Cell* *170*, 1079-1095.e1020.

- Cohen, J.D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A.A., Wong, F., Mattox, A., *et al.* (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science (New York, NY)* 359, 926-930.
- Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A.J., Barradas, M., Benguria, A., Zaballos, A., Flores, J.M., Barbacid, M., *et al.* (2005). Tumour biology: senescence in premalignant tumours. *Nature* 436, 642.
- Coombs, C.C., Zehir, A., Devlin, S.M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D.M., Solit, D.B., Robson, M.E., Baselga, J., *et al.* (2017). Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. *Cell stem cell* 21, 374-382 e374.
- Couronne, L., Bastard, C., and Bernard, O.A. (2012). TET2 and DNMT3A mutations in human T-cell lymphoma. *The New England journal of medicine* 366, 95-96.
- Cowell, I.G., and Austin, C.A. (2012). Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. *International journal of environmental research and public health* 9, 2075-2091.
- CRUK (2018). Acute myeloid leukaemia (AML) incidence statistics.
- Crusz, S.M., and Balkwill, F.R. (2015). Inflammation and cancer: advances and new agents. *Nature reviews Clinical oncology* 12, 584-596.
- Day, N., Oakes, S., Luben, R., Khaw, K.T., Bingham, S., Welch, A., and Wareham, N. (1999). EPIC-Norfolk: study design and characteristics of the cohort. *European Prospective Investigation of Cancer. British journal of cancer* 80 Suppl 1, 95-103.
- De Brakeleer, S., De Greve, J., Loris, R., Janin, N., Lissens, W., Sermijn, E., and Teugels, E. (2010). Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. *Hum Mutat* 31, E1175-1185.
- De Roos, A.J., Deeg, H.J., Onstad, L., Kopecky, K.J., Bowles, E.J., Yong, M., Fryzek, J., and Davis, S. (2010). Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. *American journal of hematology* 85, 765-770.
- Deininger, M.W.N., Tyner, J.W., and Solary, E. (2017). Turning the tide in myelodysplastic/myeloproliferative neoplasms. *Nature reviews Cancer* 17, 425-440.
- Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E., and Lippman, S.M. (2005). Statins and cancer prevention. *Nature reviews Cancer* 5, 930-942.
- Denoix, P.F. (1954). De la diversité de certains cancers. Monographie de l'Institut national d'hygiène 5.
- Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M.S., Cheang, G., Lee, S., Samuel, M., Ritchie, E.K., Guzman, M.L., Ballman, K.V., *et al.* (2018). Somatic mutations precede acute myeloid leukemia years before diagnosis. *Nature medicine* 24, 1015-1023.

- Deschler, B., and Lubbert, M. (2006). Acute myeloid leukemia: epidemiology and etiology. *Cancer* *107*, 2099-2107.
- Ding, J.H., Li, S.P., Cao, H.X., Wu, J.Z., Gao, C.M., Liu, Y.T., Zhou, J.N., Chang, J., and Yao, G.H. (2010). Alcohol dehydrogenase-2 and aldehyde dehydrogenase-2 genotypes, alcohol drinking and the risk for esophageal cancer in a Chinese population. *Journal of human genetics* *55*, 97-102.
- Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., Ritchey, J.K., Young, M.A., Lamprecht, T., McLellan, M.D., *et al.* (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature* *481*, 506-510.
- Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., *et al.* (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood* *115*, 453-474.
- Döhner, H., Weisdorf, D.J., and Bloomfield, C.D. (2015). Acute Myeloid Leukemia. *New England Journal of Medicine* *373*, 1136-1152.
- Dominguez, P.M., Ghamlouch, H., Rosikiewicz, W., Kumar, P., Beguelin, W., Fontan, L., Rivas, M.A., Pawlikowska, P., Armand, M., Mouly, E., *et al.* (2018). TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. *Cancer discovery* *8*, 1632-1653.
- Dores, G.M., Anderson, W.F., Curtis, R.E., Landgren, O., Ostroumova, E., Bluhm, E.C., Rabkin, C.S., Devesa, S.S., and Linet, M.S. (2007). Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. *British journal of haematology* *139*, 809-819.
- Doulatov, S., Notta, F., Laurenti, E., and Dick, J.E. (2012). Hematopoiesis: a human perspective. *Cell stem cell* *10*, 120-136.
- Dunn, J., Qiu, H., Kim, S., Jjingo, D., Hoffman, R., Kim, C.W., Jang, I., Son, D.J., Kim, D., Pan, C., *et al.* (2014). Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. *The Journal of clinical investigation* *124*, 3187-3199.
- Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., Radich, J., Anderson, G., and Hartwell, L. (2003). The case for early detection. *Nature reviews Cancer* *3*, 243-252.
- Fearon, E.R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. *Cell* *61*, 759-767.
- Feinberg, A.P., Koldobskiy, M.A., and Gondor, A. (2016). Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. *Nature reviews Genetics* *17*, 284-299.
- Felix, C.A. (2001). Leukemias related to treatment with DNA topoisomerase II inhibitors. *Medical and pediatric oncology* *36*, 525-535.

Felix, C.A., Hosler, M.R., Provisor, D., Salhany, K., Sexsmith, E.A., Slater, D.J., Cheung, N.K., Winick, N.J., Strauss, E.A., Heyn, R., *et al.* (1996). The p53 gene in pediatric therapy-related leukemia and myelodysplasia. *Blood* *87*, 4376-4381.

Felix, C.A., Megonigal, M.D., Chervinsky, D.S., Leonard, D.G., Tsuchida, N., Kakati, S., Block, A.M., Fisher, J., Grossi, M., Salhany, K.I., *et al.* (1998). Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. *Blood* *91*, 4451-4456.

Figuroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., *et al.* (2010a). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer cell* *18*, 553-567.

Figuroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., *et al.* (2010b). DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer cell* *17*, 13-27.

Finkel, T., Serrano, M., and Blasco, M.A. (2007). The common biology of cancer and ageing. *Nature* *448*, 767-774.

Fish, J.D., and Grupp, S.A. (2008). Stem cell transplantation for neuroblastoma. *Bone Marrow Transplant* *41*, 159-165.

Flach, J., Bakker, S.T., Mohrin, M., Conroy, P.C., Pietras, E.M., Reynaud, D., Alvarez, S., Diolaiti, M.E., Ugarte, F., Forsberg, E.C., *et al.* (2014). Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. *Nature* *512*, 198-202.

Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., *et al.* (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic acids research* *39*, D945-950.

Forsberg, L.A., Gisselsson, D., and Dumanski, J.P. (2017). Mosaicism in health and disease - clones picking up speed. *Nature reviews Genetics* *18*, 128-142.

Forsberg, L.A., Rasi, C., Razzaghian, H.R., Pakalapati, G., Waite, L., Thilbeault, K.S., Ronowicz, A., Wineinger, N.E., Tiwari, H.K., Boomsma, D., *et al.* (2012). Age-related somatic structural changes in the nuclear genome of human blood cells. *American journal of human genetics* *90*, 217-228.

Foulds, L. (1958). The natural history of cancer. *Journal of chronic diseases* *8*, 2-37.

Fox, M. (2013). Janet D. Rowley, Physician, Dies at 88; Discovered That Cancer Can Be Genetic. In *New York Times* (New York).

Frick, M., Chan, W., Arends, C.M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., *et al.* (2018). Role of Donor Clonal Hematopoiesis in

Allogeneic Hematopoietic Stem-Cell Transplantation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, JCO2018792184.

Fu, D., Calvo, J.A., and Samson, L.D. (2012). Balancing repair and tolerance of DNA damage caused by alkylating agents. *Nature reviews Cancer* 12, 104-120.

Fuchs, E. (1882). Das Sarkom des Uvealtractus. *Graefe's Archiv für Ophthalmologie* 12, 233.

Fuster, J.J., MacLauchlan, S., Zuriaga, M.A., Polackal, M.N., Ostriker, A.C., Chakraborty, R., Wu, C.L., Sano, S., Muralidharan, S., Rius, C., *et al.* (2017). Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science (New York, NY)* 355, 842-847.

Geiger, H., de Haan, G., and Florian, M.C. (2013). The ageing haematopoietic stem cell compartment. *Nature reviews Immunology* 13, 376-389.

Genovese, G., Kahler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., Chambert, K., Mick, E., Neale, B.M., Fromer, M., *et al.* (2014). Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *The New England journal of medicine* 371, 2477-2487.

Gerlinger, M., Rowan, A.J., Horswell, S., Math, M., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., *et al.* (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *The New England journal of medicine* 366, 883-892.

Gerstung, M., Beisel, C., Rechsteiner, M., Wild, P., Schraml, P., Moch, H., and Beerenwinkel, N. (2012). Reliable detection of subclonal single-nucleotide variants in tumour cell populations. *Nature communications* 3, 811.

Gerstung, M., Papaemmanuil, E., and Campbell, P.J. (2014). Subclonal variant calling with multiple samples and prior knowledge. *Bioinformatics (Oxford, England)* 30, 1198-1204.

Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V.I., Paschka, P., Heuser, M., Thol, F., Bolli, N., Ganly, P., *et al.* (2017). Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nature genetics* 49, 332-340.

Gibson, C.J., Lindsley, R.C., Tchekmedyian, V., Mar, B.G., Shi, J., Jaiswal, S., Bosworth, A., Francisco, L., He, J., Bansal, A., *et al.* (2017). Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, Jco2016716712.

Gilliland, D.G., and Griffin, J.D. (2002). The roles of FLT3 in hematopoiesis and leukemia. *Blood* 100, 1532-1542.

Gillis, N.K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S.J., Balasis, M.E., Mesa, T.E., Sallman, D.A., Lancet, J.E., *et al.* (2017). Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. *The Lancet Oncology* 18, 112-121.

- Goncalves, R.P., Rodrigues, D.G., and Maranhao, R.C. (2005). Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. *Leukemia research* 29, 955-959.
- Gore, L., Kearns, P.R., de Martino Lee, M.L., De Souza, C.A., Bertrand, Y., Hijiya, N., Stork, L.C., Chung, N.G., Cardos, R.C., Saikia, T., *et al.* (2018). Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, Jco2017759597.
- Greaves, M. (2015). Evolutionary determinants of cancer. *Cancer discovery* 5, 806-820.
- Greaves, M., Colman, S.M., Kearney, L., and Ford, A.M. (2011). Fusion genes in cord blood. *Blood* 117, 369-370; author reply 370-361.
- Greaves, M., and Maley, C.C. (2012). Clonal evolution in cancer. *Nature* 481, 306-313.
- Greaves, M.F., Maia, A.T., Wiemels, J.L., and Ford, A.M. (2003). Leukemia in twins: lessons in natural history. *Blood* 102, 2321-2333.
- Greaves, M.F., and Wiemels, J. (2003). Origins of chromosome translocations in childhood leukaemia. *Nature reviews Cancer* 3, 639-649.
- Green, D.R., Galluzzi, L., and Kroemer, G. (2011). Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. *Science (New York, NY)* 333, 1109-1112.
- Gudem, G., Van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M., Papaemmanuil, E., Brewer, D.S., Kallio, H.M., Hognas, G., Annala, M., *et al.* (2015). The evolutionary history of lethal metastatic prostate cancer. *Nature* 520, 353-357.
- Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. *Cell* 100, 57-70.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646-674.
- Haney, S.L., Upchurch, G.M., Opavska, J., Klinkebiel, D., Appiah, A.K., Smith, L.M., Heavican, T.B., Iqbal, J., Joshi, S., and Opavsky, R. (2016a). Loss of Dnmt3a induces CLL and PTCL with distinct methylomes and transcriptomes in mice. *Scientific reports* 6, 34222.
- Haney, S.L., Upchurch, G.M., Opavska, J., Klinkebiel, D., Hlady, R.A., Roy, S., Dutta, S., Datta, K., and Opavsky, R. (2016b). Dnmt3a Is a Haploinsufficient Tumor Suppressor in CD8+ Peripheral T Cell Lymphoma. *PLoS Genet* 12, e1006334.
- Hardy, P.A., and Zacharias, H. (2005). Reappraisal of the Hansemann-Boveri hypothesis on the origin of tumors. *Cell biology international* 29, 983-992.
- Harrell, F.E., Jr., Lee, K.L., and Mark, D.B. (1996). Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statistics in medicine* 15, 361-387.

Hasan, S.K., Mays, A.N., Ottone, T., Ledda, A., La Nasa, G., Cattaneo, C., Borlenghi, E., Melillo, L., Montefusco, E., Cervera, J., *et al.* (2008). Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. *Blood* 112, 3383-3390.

Hasle, H. (2016). Myelodysplastic and myeloproliferative disorders of childhood. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2016*, 598-604.

Heagerty, P.J., Lumley, T., and Pepe, M.S. (2000). Time-dependent ROC curves for censored survival data and a diagnostic marker. *Biometrics* 56, 337-344.

Hermouet, S., and Vilaine, M. (2011). The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? *Haematologica* 96, 1575-1579.

Heuser, M. (2016). Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2016*, 24-32.

Hinds, D.A., Barnholt, K.E., Mesa, R.A., Kiefer, A.K., Do, C.B., Eriksson, N., Mountain, J.L., Francke, U., Tung, J.Y., Nguyen, H.M., *et al.* (2016). Germline variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. *Blood*.

Hing, Z.A., Blachly, J.S., Goettl, V.M., Singh, G., Byrd, J.C., and Lapalombella, R. (2016). Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia. *128*, 972-972.

Ho, Y.K., Smith, R.G., Brown, M.S., and Goldstein, J.L. (1978). Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. *Blood* 52, 1099-1114.

Hoang, M.L., Chen, C.H., Sidorenko, V.S., He, J., Dickman, K.G., Yun, B.H., Moriya, M., Niknafs, N., Douville, C., Karchin, R., *et al.* (2013). Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. *Science translational medicine* 5, 197ra102.

Hoang, M.L., Kinde, I., Tomasetti, C., McMahon, K.W., Rosenquist, T.A., Grollman, A.P., Kinzler, K.W., Vogelstein, B., and Papadopoulos, N. (2016). Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. *Proceedings of the National Academy of Sciences of the United States of America* 113, 9846-9851.

Holohan, C., Van Schaeybroeck, S., Longley, D.B., and Johnston, P.G. (2013). Cancer drug resistance: an evolving paradigm. *Nature reviews Cancer* 13, 714-726.

Howlander, N., Noone, A., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Altekruse, S., Kosary, C., Ruhl, J., and Tatalovich, Z. (2011). SEER cancer statistics review, 1975–2008. Bethesda, MD: National Cancer Institute 19.

- Hsu, J.I., Dayaram, T., Tovy, A., De Braekeleer, E., Jeong, M., Wang, F., Zhang, J., Heffernan, T.P., Gera, S., Kovacs, J.J., *et al.* (2018). PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. *Cell stem cell* **23**, 700-713 e706.
- Hu, L., Li, M., Ding, Y., Pu, L., Liu, J., Xie, J., Cabanero, M., Li, J., Xiang, R., and Xiong, S. (2017). Prognostic value of RDW in cancers: a systematic review and meta-analysis. *Oncotarget* **8**, 16027-16035.
- Huang, K.L., Mashl, R.J., Wu, Y., Ritter, D.I., Wang, J., Oh, C., Paczkowska, M., Reynolds, S., Wyczalkowski, M.A., Oak, N., *et al.* (2018). Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell* **173**, 355-370.e314.
- Huet, S., Paubelle, E., Lours, C., Grange, B., Courtois, L., Chabane, K., Charlot, C., Mosnier, I., Simonet, T., Hayette, S., *et al.* (2018). Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. *Blood* **132**, 865-867.
- Hulegardh, E., Nilsson, C., Lazarevic, V., Garelius, H., Antunovic, P., Rangert Derolf, A., Mollgard, L., Uggla, B., Wennstrom, L., Wahlin, A., *et al.* (2015). Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. *American journal of hematology* **90**, 208-214.
- Hunger, S.P. (2017). CML in blast crisis: more common than we think? *Blood* **129**, 2713-2714.
- Hunter, K.W., Amin, R., Deasy, S., Ha, N.H., and Wakefield, L. (2018). Genetic insights into the morass of metastatic heterogeneity. *Nature reviews Cancer* **18**, 211-223.
- Ihara, K., Ishii, E., Eguchi, M., Takada, H., Suminoe, A., Good, R.A., and Hara, T. (1999). Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. *Proceedings of the National Academy of Sciences of the United States of America* **96**, 3132-3136.
- Inoue, K., and Fry, E.A. (2017). Haploinsufficient tumor suppressor genes. *Advances in medicine and biology* **118**, 83-122.
- Irminger-Finger, I., and Jefford, C.E. (2006). Is there more to BARD1 than BRCA1? *Nature reviews Cancer* **6**, 382-391.
- Itzhar, N., Dessen, P., Toujani, S., Auger, N., Preudhomme, C., Richon, C., Lazar, V., Saada, V., Bennaceur, A., Bourhis, J.H., *et al.* (2011). Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH. *PloS one* **6**, e16623.
- Jacobs, K.B., Yeager, M., Zhou, W., Wacholder, S., Wang, Z., Rodriguez-Santiago, B., Hutchinson, A., Deng, X., Liu, C., Horner, M.J., *et al.* (2012). Detectable clonal mosaicism and its relationship to aging and cancer. *Nature genetics* **44**, 651-658.

Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., Lindsley, R.C., Mermel, C.H., Burt, N., Chavez, A., *et al.* (2014). Age-related clonal hematopoiesis associated with adverse outcomes. *The New England journal of medicine* 371, 2488-2498.

Jaiswal, S., Natarajan, P., Silver, A.J., Gibson, C.J., Bick, A.G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., *et al.* (2017). Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *The New England journal of medicine* 377, 111-121.

Jan, M., Snyder, T.M., Corces-Zimmerman, M.R., Vyas, P., Weissman, I.L., Quake, S.R., and Majeti, R. (2012). Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. *Science translational medicine* 4, 149ra118.

Jeong, M., Park, H.J., Celik, H., Ostrander, E.L., Reyes, J.M., Guzman, A., Rodriguez, B., Lei, Y., Lee, Y., Ding, L., *et al.* (2018). Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. *Cell reports* 23, 1-10.

Jones, A.V., Chase, A., Silver, R.T., Osci, D., Zoi, K., Wang, Y.L., Cario, H., Pahl, H.L., Collins, A., Reiter, A., *et al.* (2009). JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. *Nature genetics* 41, 446-449.

Jones, D., Raine, K.M., Davies, H., Tarpey, P.S., Butler, A.P., Teague, J.W., Nik-Zainal, S., and Campbell, P.J. (2016). cgpaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data. *Current protocols in bioinformatics* 56, 15.10.11-15.10.18.

Ju, Y.S., Martincorena, I., Gerstung, M., Petljak, M., Alexandrov, L.B., Rahbari, R., Wedge, D.C., Davies, H.R., Ramakrishna, M., Fullam, A., *et al.* (2017). Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. *Nature* 543, 714-718.

Kahn, J.D., Miller, P.G., Silver, A.J., Sellar, R.S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., *et al.* (2018). PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. *Blood* 132, 1095-1105.

Kalmanti, L., Saussele, S., Lauseker, M., Muller, M.C., Dietz, C.T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S.W., *et al.* (2015). Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. *Leukemia* 29, 1123-1132.

Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., *et al.* (2013). Mutational landscape and significance across 12 major cancer types. *Nature* 502, 333-339.

Kardos, G., Baumann, I., Passmore, S.J., Locatelli, F., Hasle, H., Schultz, K.R., Stary, J., Schmitt-Graeff, A., Fischer, A., Harbott, J., *et al.* (2003). Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. *Blood* 102, 1997-2003.

Karoulia, Z., Gavathiotis, E., and Poulidakos, P.I. (2017). New perspectives for targeting RAF kinase in human cancer. *Nature reviews Cancer* 17, 676-691.

Kennedy, J.A., and Ebert, B.L. (2017). Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 35, 968-974.

Kennedy, S.R., Schmitt, M.W., Fox, E.J., Kohn, B.F., Salk, J.J., Ahn, E.H., Prindle, M.J., Kuong, K.J., Shen, J.-C., Risques, R.-A., *et al.* (2014). Detecting ultralow-frequency mutations by Duplex Sequencing. *Nat Protocols* 9, 2586-2606.

Kilpivaara, O., Mukherjee, S., Schram, A.M., Wadleigh, M., Mullally, A., Ebert, B.L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., *et al.* (2009). A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. *Nature genetics* 41, 455-459.

Kim, K.H., and Roberts, C.W. (2016). Targeting EZH2 in cancer. *Nature medicine* 22, 128-134.

Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W., and Vogelstein, B. (2011). Detection and quantification of rare mutations with massively parallel sequencing. *Proceedings of the National Academy of Sciences of the United States of America* 108, 9530-9535.

Knudson, A.G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. *Proceedings of the National Academy of Sciences of the United States of America* 68, 820-823.

Ko, M., Bandukwala, H.S., An, J., Lamperti, E.D., Thompson, E.C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S.B., and Rao, A. (2011). Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. *Proceedings of the National Academy of Sciences of the United States of America* 108, 14566-14571.

Koboldt, D.C., Zhang, Q., Larson, D.E., Shen, D., McLellan, M.D., Lin, L., Miller, C.A., Mardis, E.R., Ding, L., and Wilson, R.K. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome research* 22, 568-576.

Koren, A., Handsaker, R.E., Kamitaki, N., Karlic, R., Ghosh, S., Polak, P., Eggen, K., and McCarroll, S.A. (2014). Genetic variation in human DNA replication timing. *Cell* 159, 1015-1026.

Kozarewa, I., Ning, Z., Quail, M.A., Sanders, M.J., Berriman, M., and Turner, D.J. (2009). Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes. *Nature methods* 6, 291-295.

Kronke, J., Bullinger, L., Teleanu, V., Tschurtz, F., Gaidzik, V.I., Kuhn, M.W., Rucker, F.G., Holzmann, K., Paschka, P., Kapp-Schworer, S., *et al.* (2013). Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. *Blood* 122, 100-108.

Krontiris, T.G., and Cooper, G.M. (1981). Transforming activity of human tumor DNAs. *Proceedings of the National Academy of Sciences of the United States of America* 78, 1181-1184.

Kushner, B.H., Cheung, N.K., Kramer, K., Heller, G., and Jhanwar, S.C. (1998). Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 16, 3880-3889.

Landau, D.A., Tausch, E., Taylor-Weiner, A.N., Stewart, C., Reiter, J.G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Bottcher, S., *et al.* (2015). Mutations driving CLL and their evolution in progression and relapse. *Nature* 526, 525-530.

Landau, D.A., and Wu, C.J. (2013). Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. *Genome medicine* 5, 47.

Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., *et al.* (2001). Initial sequencing and analysis of the human genome. *Nature* 409, 860-921.

Landgren, O., Albitar, M., Ma, W., Abbasi, F., Hayes, R.B., Ghia, P., Marti, G.E., and Caporaso, N.E. (2009). B-cell clones as early markers for chronic lymphocytic leukemia. *The New England journal of medicine* 360, 659-667.

Landrum, M.J., Lee, J.M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., *et al.* (2016). ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic acids research* 44, D862-868.

Latchney, S.E., and Calvi, L.M. (2017). The aging hematopoietic stem cell niche: Phenotypic and functional changes and mechanisms that contribute to hematopoietic aging. *Seminars in hematology* 54, 25-32.

Laurie, C.C., Laurie, C.A., Rice, K., Doheny, K.F., Zelnick, L.R., McHugh, C.P., Ling, H., Hetrick, K.N., Pugh, E.W., Amos, C., *et al.* (2012). Detectable clonal mosaicism from birth to old age and its relationship to cancer. *Nature genetics* 44, 642-650.

Lausten-Thomsen, U., Madsen, H.O., Vestergaard, T.R., Hjalgrim, H., Nersting, J., and Schmiegelow, K. (2011). Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates. *Blood* 117, 186-189.

Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., *et al.* (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 499, 214-218.

Le Deley, M.C., Leblanc, T., Shamsaldin, A., Raquin, M.A., Lacour, B., Sommelet, D., Chompret, A., Cayuela, J.M., Bayle, C., Bernheim, A., *et al.* (2003). Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21, 1074-1081.

Lee, S.C., Dvinge, H., Kim, E., Cho, H., Micol, J.B., Chung, Y.R., Durham, B.H., Yoshimi, A., Kim, Y.J., Thomas, M., *et al.* (2016). Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. *Nature medicine* 22, 672-678.

Lee-Six, H., Obro, N.F., Shepherd, M.S., Grossmann, S., Dawson, K., Belmonte, M., Osborne, R.J., Huntly, B.J.P., Martincorena, I., Anderson, E., *et al.* (2018). Population dynamics of normal human blood inferred from somatic mutations. *Nature* 561, 473-478.

Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics (Oxford, England)* 25, 1754-1760.

Li, H., and Durbin, R. (2010). Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics (Oxford, England)* 26, 589-595.

Li, Y., Roberts, N., Weischenfeldt, J., Wala, J.A., Shapira, O., Schumacher, S., Khurana, E., Korb, J.O., Imielinski, M., Beroukhi, R., *et al.* (2017). Patterns of structural variation in human cancer. *bioRxiv*.

Lim, U., Gayles, T., Katki, H.A., Stolzenberg-Solomon, R., Weinstein, S.J., Pietinen, P., Taylor, P.R., Virtamo, J., and Albanes, D. (2007). Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. *Cancer research* 67, 5569-5574.

Link, D.C., and Walter, M.J. (2016). /³CHIP/³ping away at clonal hematopoiesis. *Leukemia* 30, 1633-1635.

Locatelli, F., and Strahm, B. (2018). How I treat myelodysplastic syndromes of childhood. *Blood* 131, 1406-1414.

Loftfield, E., Zhou, W., Graubard, B.I., Yeager, M., Chanock, S.J., Freedman, N.D., and Machiela, M.J. (2018a). Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. *Scientific reports* 8, 12316.

Loftfield, E., Zhou, W., Yeager, M., Chanock, S.J., Freedman, N.D., and Machiela, M.J. (2018b). Mosaic Y loss is moderately associated with solid tumor risk. *Cancer research*.

Loh, P.R., Genovese, G., Handsaker, R.E., Finucane, H.K., Reshef, Y.A., Palamara, P.F., Birmann, B.M., Talkowski, M.E., Bakhoun, S.F., McCarroll, S.A., *et al.* (2018). Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. *Nature* 559, 350-355.

Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. *Cell* 153, 1194-1217.

Lu, C., Xie, M., Wendl, M.C., Wang, J., McLellan, M.D., Leiserson, M.D.M., Huang, K.-I., Wyczalkowski, M.A., Jayasinghe, R., Banerjee, T., *et al.* (2015). Patterns and functional implications of rare germline variants across 12 cancer types. *Nature communications* 6.

- Lunning, M.A., and Green, M.R. (2015). Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. *Blood cancer journal* 5, e361.
- Ma, J., Setton, J., Lee, N.Y., Riaz, N., and Powell, S.N. (2018). The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. *Nature communications* 9, 3292.
- Machiela, M.J., Zhou, W., Sampson, J.N., Dean, M.C., Jacobs, K.B., Black, A., Brinton, L.A., Chang, I.S., Chen, C., Chen, C., *et al.* (2015). Characterization of large structural genetic mosaicism in human autosomes. *American journal of human genetics* 96, 487-497.
- Maher, O.M., Silva, J.G., Wu, J., Liu, D., Cooper, L.J., Tarek, N., Worth, L., Lee, D.A., Petropoulos, D., Franklin, A.R., *et al.* (2017). Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. *Pediatric transplantation* 21.
- Makohon-Moore, A., and Iacobuzio-Donahue, C.A. (2016). Pancreatic cancer biology and genetics from an evolutionary perspective. *Nature reviews Cancer* 16, 553-565.
- Manchester, K.L. (1995). Theodor Boveri and the origin of malignant tumours. *Trends in cell biology* 5, 384-387.
- Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., and Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. *Nature reviews Clinical oncology* 14, 399-416.
- Maris, J.M. (2015). Defining Why Cancer Develops in Children. *New England Journal of Medicine* 373, 2373-2375.
- Maris, J.M., and Knudson, A.G. (2015). Revisiting tissue specificity of germline cancer predisposing mutations. *Nature reviews Cancer* 15, 65-66.
- Martincorena, I., and Campbell, P.J. (2015). Somatic mutation in cancer and normal cells. *Science (New York, NY)* 349, 1483-1489.
- Martincorena, I., Fowler, J.C., Wabik, A., Lawson, A.R.J., Abascal, F., Hall, M.W.J., Cagan, A., Murai, K., Mahbubani, K., Stratton, M.R., *et al.* (2018). Somatic mutant clones colonize the human esophagus with age. *Science (New York, NY)* 362, 911-917.
- Martincorena, I., Raine, K.M., Gerstung, M., Dawson, K.J., Haase, K., Van Loo, P., Davies, H., Stratton, M.R., and Campbell, P.J. (2017). Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell* 171, 1029-1041 e1021.
- Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D.C., Fullam, A., Alexandrov, L.B., Tubio, J.M., *et al.* (2015). Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. *Science (New York, NY)* 348, 880-886.

Matsuo, T., Tashiro, H., Sumiyoshi, R., Yamamoto, T., Oka-Miura, Y., Matsumoto, K., Ooi, J., and Shirafuji, N. (2017). Low High-Density Lipoprotein Cholesterol (HDL) Is a Significant Poor Prognostic Factor in Malignant Lymphoma. *130*, 5148-5148.

Matthay, K.K., Maris, J.M., Schleiermacher, G., Nakagawara, A., Mackall, C.L., Diller, L., and Weiss, W.A. (2016). Neuroblastoma. *Nature reviews Disease primers* 2, 16078.

Mattox, A.K., Wang, Y., Springer, S., Cohen, J.D., Yegnasubramanian, S., Nelson, W.G., Kinzler, K.W., Vogelstein, B., and Papadopoulos, N. (2017). Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. *Proceedings of the National Academy of Sciences of the United States of America* 114, 4733-4738.

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., *et al.* (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome research* 20, 1297-1303.

McKerrell, T., Moreno, T., Ponstingl, H., Bolli, N., Dias, J.M., Tischler, G., Colonna, V., Manasse, B., Bench, A., Bloxham, D., *et al.* (2016). Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. *Blood*.

McKerrell, T., Park, N., Chi, J., Collord, G., Moreno, T., Ponstingl, H., Dias, J., Gerasimou, P., Melanthiou, K., Prokopiou, C., *et al.* (2017). JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. *Blood Adv* 1, 968-971.

McKerrell, T., Park, N., Moreno, T., Grove, C.S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M.A., Hodgkinson, C., *et al.* (2015). Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell reports* 10, 1239-1245.

McKerrell, T., and Vassiliou, G.S. (2015). Aging as a driver of leukemogenesis. *Science translational medicine* 7, 306fs338.

McMahon, K.M., Scielzo, C., Angeloni, N.L., Deiss-Yehiely, E., Scarfo, L., Ronghetti, P., Ma, S., Kaplan, J., Barboglio, F., Gordon, L.I., *et al.* (2017). Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. *Oncotarget* 8, 11219-11227.

McNerney, M.E., Godley, L.A., and Le Beau, M.M. (2017). Therapy-related myeloid neoplasms: when genetics and environment collide. *Nature reviews Cancer* 17, 513-527.

Medinger, M., and Passweg, J.R. (2017). Acute myeloid leukaemia genomics. *British journal of haematology* 179, 530-542.

Medyouf, H. (2017). The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. *Blood* 129, 1617-1626.

Megonigal, M.D., Cheung, N.K., Rappaport, E.F., Nowell, P.C., Wilson, R.B., Jones, D.H., Addya, K., Leonard, D.G., Kushner, B.H., Williams, T.M., *et al.* (2000). Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II

inhibitors. *Proceedings of the National Academy of Sciences of the United States of America* 97, 2814-2819.

Mehta, P.A., Harris, R.E., Davies, S.M., Kim, M.O., Mueller, R., Lampkin, B., Mo, J., Myers, K., and Smolarek, T.A. (2010). Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia. *Cancer genetics and cytogenetics* 203, 180-186.

Menzies, A., Teague, J.W., Butler, A.P., Davies, H., Tarpey, P., Nik-Zainal, S., and Campbell, P.J. (2002). VAGrENT: Variation Annotation Generator. In *Current protocols in bioinformatics* (John Wiley & Sons, Inc.).

Metzeler, K.H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M.C., Gorlich, D., Schneider, S., Konstandin, N.P., Dufour, A., Braundl, K., *et al.* (2016). Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood* 128, 686-698.

Mistry, A.R., Felix, C.A., Whitmarsh, R.J., Mason, A., Reiter, A., Cassinat, B., Parry, A., Walz, C., Wiemels, J.L., Segal, M.R., *et al.* (2005). DNA topoisomerase II in therapy-related acute promyelocytic leukemia. *The New England journal of medicine* 352, 1529-1538.

Mitchell, T.J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J.H.R., O'Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L.R., *et al.* (2018). Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. *Cell* 173, 611-623.e617.

Moore, L., Leongamornlert, D., Coorens, T.H., Sanders, M.A., Ellis, P., Dawson, K., Maura, F., Nangalia, J., Tarpey, P.S., Brunner, S.F., *et al.* (2018). The mutational landscape of normal human endometrial epithelium. 505685.

Moran-Crusio, K. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer cell* 20, 11-24.

Mori, H., Colman, S.M., Xiao, Z., Ford, A.M., Healy, L.E., Donaldson, C., Hows, J.M., Navarrete, C., and Greaves, M. (2002). Chromosome translocations and covert leukemic clones are generated during normal fetal development. *Proceedings of the National Academy of Sciences of the United States of America* 99, 8242-8247.

Morton, L.M., Curtis, R.E., Linet, M.S., Bluhm, E.C., Tucker, M.A., Caporaso, N., Ries, L.A., and Fraumeni, J.F., Jr. (2010). Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 28, 4935-4944.

Morton, L.M., Dores, G.M., Schonfeld, S.J., Linet, M.S., Sigel, B.S., Lam, C.J.K., Tucker, M.A., and Curtis, R.E. (2018). Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. *JAMA Oncol.*

Morton, L.M., Gibson, T.M., Clarke, C.A., Lynch, C.F., Anderson, L.A., Pfeiffer, R., Landgren, O., Weisenburger, D.D., and Engels, E.A. (2014). Risk of myeloid neoplasms after solid organ transplantation. *Leukemia* 28, 2317-2323.

Mouly, E., Ghamlouch, H., Della-Valle, V., Scourzic, L., Quivoron, C., Roos-Weil, D., Pawlikowska, P., Saada, V., Diop, M.K., Lopez, C.K., *et al.* (2018). B-cell tumor development in Tet2-deficient mice. *Blood Adv* 2, 703-714.

Mullighan, C.G. (2014). The genomic landscape of acute lymphoblastic leukemia in children and young adults. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2014*, 174-180.

Murai, K., Skrupskelyte, G., Piedrafita, G., Hall, M., Kostiou, V., Ong, S.H., Nagy, T., Cagan, A., Goulding, D., Klein, A.M., *et al.* (2018). Epidermal Tissue Adapts to Restrain Progenitors Carrying Clonal p53 Mutations. *Cell stem cell* 23, 687-699.e688.

Nachmanson, D., Lian, S., Schmidt, E.K., Hipp, M.J., Baker, K.T., Zhang, Y., Tretiakova, M., Loubet-Seneor, K., Kohn, B.F., Salk, J.J., *et al.* (2018). Targeted genome fragmentation with CRISPR/Cas9 enables fast and efficient enrichment of small genomic regions and ultra-accurate sequencing with low DNA input (CRISPR-DS). *Genome research* 28, 1589-1599.

Nangalia, J., Grinfeld, J., and Green, A.R. (2016). Pathogenesis of Myeloproliferative Disorders. *Annual review of pathology* 11, 101-126.

Nangalia, J., Mitchell, E., and Green, A.R. (2019). Clonal approaches to understanding the impact of mutations on hematologic disease development. *Blood*.

Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., *et al.* (2011). Tumour evolution inferred by single-cell sequencing. *Nature* 472, 90-94.

Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., Liu, C.L., Neal, J.W., Wakelee, H.A., Merritt, R.E., *et al.* (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nature medicine* 20, 548-554.

Newman, A.M., Lovejoy, A.F., Klass, D.M., Kurtz, D.M., Chabon, J.J., Scherer, F., Stehr, H., Liu, C.L., Bratman, S.V., Say, C., *et al.* (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. *Nat Biotech* 34, 547-555.

Ng, A., Ravetto, P.F., Taylor, G.M., Wynn, R.F., and Eden, O.B. (2004). Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis. *British journal of cancer* 91, 1990-1992.

Niemeyer, C.M., and Baumann, I. (2011). Classification of childhood aplastic anemia and myelodysplastic syndrome. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011*, 84-89.

Nik-Zainal, S. (2014). Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. *Nat Genet* 46, 487-491.

Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., *et al.* (2012). The life history of 21 breast cancers. *Cell* 149, 994-1007.

Nordling, C.O. (1953). A new theory on cancer-inducing mechanism. *British journal of cancer* 7, 68-72.

Nowell, P., and Hungerford, D. (1960). A minute chromosome in human granulocytic leukemia. *Science (New York, NY)* 132, 1497.

Nowell, P.C. (1976). The clonal evolution of tumor cell populations. *Science (New York, NY)* 194, 23-28.

O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., *et al.* (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *The New England journal of medicine* 348, 994-1004.

O'Quigley, J., Xu, R., and Stare, J. (2005). Explained randomness in proportional hazards models. *Statistics in medicine* 24, 479-489.

Oeffinger, K.C., Mertens, A.C., Sklar, C.A., Kawashima, T., Hudson, M.M., Meadows, A.T., Friedman, D.L., Marina, N., Hobbie, W., Kadan-Lottick, N.S., *et al.* (2006). Chronic health conditions in adult survivors of childhood cancer. *The New England journal of medicine* 355, 1572-1582.

Offman, J., Opelz, G., Doehler, B., Cummins, D., Halil, O., Banner, N.R., Burke, M.M., Sullivan, D., Macpherson, P., and Karran, P. (2004). Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. *Blood* 104, 822-828.

Ojha, J., Secreto, C., Rabe, K., Ayres-Silva, J., Tschumper, R., Dyke, D.V., Slager, S., Fonseca, R., Shanafelt, T., Kay, N., *et al.* (2014). Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. *Leukemia* 28, 2395-2398.

Ok, C.Y., Patel, K.P., Garcia-Manero, G., Routbort, M.J., Peng, J., Tang, G., Goswami, M., Young, K.H., Singh, R., Medeiros, L.J., *et al.* (2015). TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. *Journal of hematology & oncology* 8, 45.

Okosun, J., Bodor, C., Wang, J., Araf, S., Yang, C.Y., Pan, C., Boller, S., Cittaro, D., Bozek, M., Iqbal, S., *et al.* (2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. *Nature genetics* 46, 176-181.

- Olcaydu, D., Harutyunyan, A., Jager, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H., and Kralovics, R. (2009). A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. *Nature genetics* *41*, 450-454.
- Osorio, F.G., Rosendahl Huber, A., Oka, R., Verheul, M., Patel, S.H., Hasaart, K., de la Fonteijne, L., Varela, I., Camargo, F.D., and van Boxtel, R. (2018). Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis. *Cell reports* *25*, 2308-2316.e2304.
- Paget, S. (1889). The distribution of secondary growths in cancer of the breast. *The Lancet* *133*, 571-573.
- Pan, F., Wingo, T.S., Zhao, Z., Gao, R., Makishima, H., Qu, G., Lin, L., Yu, M., Ortega, J.R., Wang, J., *et al.* (2017). Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nature communications* *8*, 15102.
- Pandya, A., Mullen, P.J., Kalkat, M., Yu, R., Pong, J.T., Li, Z., Trudel, S., Lang, K.S., Minden, M.D., Schimmer, A.D., *et al.* (2014). Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. *Cancer research* *74*, 4772-4782.
- Pang, W.W., Price, E.A., Sahoo, D., Beerman, I., Maloney, W.J., Rossi, D.J., Schrier, S.L., and Weissman, I.L. (2011). Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. *Proceedings of the National Academy of Sciences of the United States of America* *108*, 20012-20017.
- Pang, W.W., Schrier, S.L., and Weissman, I.L. (2017). Age-associated changes in human hematopoietic stem cells. *Seminars in hematology* *54*, 39-42.
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., Potter, N.E., Heuser, M., Thol, F., Bolli, N., *et al.* (2016). Genomic Classification and Prognosis in Acute Myeloid Leukemia. *New England Journal of Medicine* *374*, 2209-2221.
- Park, N., and Vassiliou, G. (2017). Design and Application of Multiplex PCR Seq for the Detection of Somatic Mutations Associated with Myeloid Malignancies. *Methods in molecular biology* *1633*, 87-99.
- Parkin, B., Londono-Joshi, A., Kang, Q., Tewari, M., Rhim, A.D., and Malek, S.N. (2017). Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. *The Journal of clinical investigation* *127*, 3484-3495.
- Parsons, D.W., Roy, A., Yang, Y., Wang, T., Scollon, S., Bergstrom, K., Kerstein, R.A., Gutierrez, S., Petersen, A.K., Bavle, A., *et al.* (2016). Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. *JAMA Oncol* *2*.
- Pastor, V., Hirabayashi, S., Karow, A., Wehrle, J., Kozyra, E.J., Nienhold, R., Ruzaike, G., Lebrecht, D., Yoshimi, A., Niewisch, M., *et al.* (2017). Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. *Leukemia* *31*, 759-762.

Petljak, M., and Alexandrov, L.B. (2016). Understanding mutagenesis through delineation of mutational signatures in human cancer. *Carcinogenesis* 37, 531-540.

Petljak, M., Butler, A.P., Bolli, N., Davies, H.R., Knappskog, S., Martin, S., Papaemmanuil, E., Ramakrishna, M., Shlien, A., Simonic, I., *et al.* (2014). Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. *Nature genetics* 24, 52-60.

Petti, A.A., Williams, S.R., Miller, C.A., Fiddes, I.T., Srivatsan, S.N., Chen, D.Y., Fronick, C.C., Fulton, R.S., Church, D.M., and Ley, T.J. (2018). Mutation detection in thousands of acute myeloid leukemia cells using single cell RNA-sequencing.

Pinzaru, A.M., Hom, R.A., Beal, A., Phillips, A.F., Ni, E., Cardozo, T., Nair, N., Choi, J., Wuttke, D.S., Sfeir, A., *et al.* (2016). Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis. *Cell reports* 15, 2170-2184.

Pirro, M., Ricciuti, B., Rader, D.J., Catapano, A.L., Sahebkar, A., and Banach, M. (2018). High density lipoprotein cholesterol and cancer: Marker or causative? *Progress in lipid research* 71, 54-69.

Poon, S.L., Huang, M.N., Choo, Y., McPherson, J.R., Yu, W., Heng, H.L., Gan, A., Myint, S.S., Siew, E.Y., Ler, L.D., *et al.* (2015). Mutation signatures implicate aristolochic acid in bladder cancer development. *Genome medicine* 7, 38.

Potter, N.E., Ermini, L., Papaemmanuil, E., Cazzaniga, G., Vijayaraghavan, G., Tittley, I., Ford, A., Campbell, P., Kearney, L., and Greaves, M. (2013). Single-cell mutational profiling and clonal phylogeny in cancer. *Genome research* 23, 2115-2125.

Poynter, J.N., Gruber, S.B., Higgins, P.D., Almog, R., Bonner, J.D., Rennert, H.S., Low, M., Greenson, J.K., and Rennert, G. (2005). Statins and the risk of colorectal cancer. *The New England journal of medicine* 352, 2184-2192.

Pritchard, C.C., Mateo, J., Walsh, M.F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., *et al.* (2016). Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine* 375, 443-453.

Pui, C.H., Ribeiro, R.C., Hancock, M.L., Rivera, G.K., Evans, W.E., Raimondi, S.C., Head, D.R., Behm, F.G., Mahmoud, M.H., Sandlund, J.T., *et al.* (1991). Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. *The New England journal of medicine* 325, 1682-1687.

Qu, W., and Zhang, C. (2015). Selecting specific PCR primers with MFEprimer. *Methods in molecular biology* 1275, 201-213.

Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics (Oxford, England)* 26, 841-842.

Quivoron, C., Couronne, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., *et al.* (2011). TET2 inactivation results

in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer cell* 20, 25-38.

Raine, K.M., Hinton, J., Butler, A.P., Teague, J.W., Davies, H., Tarpey, P., Nik-Zainal, S., and Campbell, P.J. (2015). cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events from Paired End Sequencing. *Current protocols in bioinformatics* 52, 15.17.11-12.

Ramus, S.J., Song, H., Dicks, E., Tyrer, J.P., Rosenthal, A.N., Intermaggio, M.P., Fraser, L., Gentry-Maharaj, A., Hayward, J., Philpott, S., *et al.* (2015). Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *Journal of the National Cancer Institute* 107.

Rawstron, A.C., Bennett, F.L., O'Connor, S.J., Kwok, M., Fenton, J.A., Plummer, M., de Tute, R., Owen, R.G., Richards, S.J., Jack, A.S., *et al.* (2008). Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. *The New England journal of medicine* 359, 575-583.

Raza, A., and Galili, N. (2012). The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. *Nature reviews Cancer* 12, 849-859.

Reddy, A., Zhang, J., Davis, N.S., Moffitt, A.B., Love, C.L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.L., *et al.* (2017). Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. *Cell* 171, 481-494.e415.

Reddy, E.P., Reynolds, R.K., Santos, E., and Barbacid, M. (1982). A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. *Nature* 300, 149-152.

Reina-Castillon, J., Pujol, R., Lopez-Sanchez, M., Rodriguez-Santiago, B., Aza-Carmona, M., Gonzalez, J.R., Casado, J.A., Bueren, J.A., Sevilla, J., Badel, I., *et al.* (2017). Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. *Blood Adv* 1, 319-329.

Riboli, E., Hunt, K.J., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondiere, U.R., Hemon, B., Casagrande, C., Vignat, J., *et al.* (2002). European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public health nutrition* 5, 1113-1124.

Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S.D., *et al.* (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *The New England journal of medicine* 377, 1119-1131.

Robinson, B.W., Cheung, N.K., Kolaris, C.P., Jhanwar, S.C., Choi, J.K., Osheroff, N., and Felix, C.A. (2008). Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. *Blood* 111, 3802-3812.

Rodriguez-Santiago, B., Malats, N., Rothman, N., Armengol, L., Garcia-Closas, M., Kogevinas, M., Villa, O., Hutchinson, A., Earl, J., Marenne, G., *et al.* (2010). Mosaic uniparental disomies

and aneuploidies as large structural variants of the human genome. *American journal of human genetics* *87*, 129-138.

Roerink, S.F., Sasaki, N., Lee-Six, H., Young, M.D., Alexandrov, L.B., Behjati, S., Mitchell, T.J., Grossmann, S., Lightfoot, H., Egan, D.A., *et al.* (2018). Intra-tumour diversification in colorectal cancer at the single-cell level. *Nature* *556*, 457-462.

Roos, W.P., Thomas, A.D., and Kaina, B. (2016). DNA damage and the balance between survival and death in cancer biology. *Nature reviews Cancer* *16*, 20-33.

Ross, M.G., Russ, C., Costello, M., Hollinger, A., Lennon, N.J., Hegarty, R., Nusbaum, C., and Jaffe, D.B. (2013). Characterizing and measuring bias in sequence data. *Genome biology* *14*, R51.

Ross, R. (1999). Atherosclerosis--an inflammatory disease. *The New England journal of medicine* *340*, 115-126.

Rossi, D.J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., and Weissman, I.L. (2007). Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature* *447*, 725-729.

Rossi, D.J., Bryder, D., Zahn, J.M., Ahlenius, H., Sonu, R., Wagers, A.J., and Weissman, I.L. (2005). Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proceedings of the National Academy of Sciences of the United States of America* *102*, 9194-9199.

Rowland, J.H., and Bellizzi, K.M. (2014). Cancer survivorship issues: life after treatment and implications for an aging population. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* *32*, 2662-2668.

Rowley, J.D. (1973). Identification of a Translocation with Quinacrine Fluorescence in a Patient with Acute Leukemia. *Annales De Genetique* *16*, 109-112.

Rowley, J.D. (2001). Chromosome translocations: dangerous liaisons revisited. *Nature reviews Cancer* *1*, 245-250.

Rowley, J.D. (2008). Chromosomal translocations: revisited yet again. *Blood* *112*, 2183-2189.

Rozhok, A.I., and DeGregori, J. (2015). Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. *Proceedings of the National Academy of Sciences of the United States of America* *112*, 8914-8921.

Rozhok, A.I., Salstrom, J.L., and DeGregori, J. (2014). Stochastic modeling indicates that aging and somatic evolution in the hematopoietic system are driven by non-cell-autonomous processes. *Aging (Albany NY)* *6*, 1033-1048.

Ruark, E., Snape, K., Humburg, P., Loveday, C., Bajrami, I., Brough, R., Rodrigues, D.N., Renwick, A., Seal, S., Ramsay, E., *et al.* (2013). Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. *Nature* *493*, 406-410.

Rubnitz, J.E., Inaba, H., Leung, W.H., Pounds, S., Cao, X., Campana, D., Ribeiro, R.C., and Pui, C.H. (2014). Definition of cure in childhood acute myeloid leukemia. *Cancer* 120, 2490-2496.

Sabarathan, R., Pich, O., Martincorena, I., Rubio-Perez, C., Juul, M., Wala, J., Schumacher, S., Shapira, O., Sidiropoulos, N., Waszak, S., *et al.* (2017). The whole-genome panorama of cancer drivers. *bioRxiv*.

Saliba, J., Saint-Martin, C., Di Stefano, A., Lenglet, G., Marty, C., Keren, B., Pasquier, F., Valle, V.D., Secardin, L., Leroy, G., *et al.* (2015). Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. *Nature genetics* 47, 1131-1140.

Salk, J.J., Loubet-Senear, K., Maritschnegg, E., Valentine, C.C., Williams, L.N., Horvat, R., Vanderstichele, A., Nachmanson, D., Baker, K.T., Emond, M.J., *et al.* (2018). Ultra-sensitive sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan.

Salvagno, G.L., Sanchis-Gomar, F., Picanza, A., and Lippi, G. (2015). Red blood cell distribution width: A simple parameter with multiple clinical applications. *Critical reviews in clinical laboratory sciences* 52, 86-105.

Sano, S., Oshima, K., Wang, Y., MacLauchlan, S., Katanasaka, Y., Sano, M., Zuriaga, M.A., Yoshiyama, M., Goukassian, D., Cooper, M.A., *et al.* (2018a). Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome. *J Am Coll Cardiol* 71, 875-886.

Sano, S., Wang, Y., and Walsh, K. (2018b). Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. *Circulation journal : official journal of the Japanese Circulation Society* 83, 2-11.

Savola, P., Kelkka, T., Rajala, H.L., Kuuliala, A., Kuuliala, K., Eldfors, S., Ellonen, P., Lagstrom, S., Lepisto, M., Hannunen, T., *et al.* (2017). Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. *Nature communications* 8, 15869.

Schick, U.M., McDavid, A., Crane, P.K., Weston, N., Ehrlich, K., Newton, K.M., Wallace, R., Bookman, E., Harrison, T., Aragaki, A., *et al.* (2013). Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. *PLoS one* 8, e59823.

Schmitt, M.W., Fox, E.J., Prindle, M.J., Reid-Bayliss, K.S., True, L.D., Radich, J.P., and Loeb, L.A. (2015). Sequencing small genomic targets with high efficiency and extreme accuracy. *Nature methods* 12, 423-425.

Schmitt, M.W., Kennedy, S.R., Salk, J.J., Fox, E.J., Hiatt, J.B., and Loeb, L.A. (2012). Detection of ultra-rare mutations by next-generation sequencing. *Proceedings of the National Academy of Sciences of the United States of America* 109, 14508-14513.

Schmitt, M.W., Loeb, L.A., and Salk, J.J. (2016). The influence of subclonal resistance mutations on targeted cancer therapy. *Nature reviews Clinical oncology* 13, 335-347.

Schrader, K.A., Cheng, D.T., Joseph, V., Prasad, M., Walsh, M., Zehir, A., Ni, A., Thomas, T., Benayed, R., Ashraf, A., *et al.* (2016). Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. *JAMA Oncol* 2, 104-111.

Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science (New York, NY)* 331, 1565-1570.

Schulz, E., Kashofer, K., Heitzer, E., Mhatre, K.N., Speicher, M.R., Hoefler, G., and Sill, H. (2015). Preexisting TP53 mutation in therapy-related acute myeloid leukemia. *Annals of hematology* 94, 527-529.

Schulz, E., Valentin, A., Ulz, P., Beham-Schmid, C., Lind, K., Rupp, V., Lackner, H., Wolfler, A., Zebisch, A., Olipitz, W., *et al.* (2012). Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. *Journal of medical genetics* 49, 422-428.

Schwartzmann, G., Brondani da Rocha, A., Berlinck, R.G., and Jimeno, J. (2001). Marine organisms as a source of new anticancer agents. *The Lancet Oncology* 2, 221-225.

Scott, D.W., and Gascoyne, R.D. (2014). The tumour microenvironment in B cell lymphomas. *Nature reviews Cancer* 14, 517-534.

SEER (2018). Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML).

Shaw, A.C., Goldstein, D.R., and Montgomery, R.R. (2013). Age-dependent dysregulation of innate immunity. *Nature reviews Immunology* 13, 875-887.

Shen, L., Shi, Q., and Wang, W. (2018). Double agents: genes with both oncogenic and tumor-suppressor functions. *Oncogenesis* 7, 25.

Shen, R., and Seshan, V.E. (2016). FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. *Nucleic acids research* 44, e131.

Shen, Z., Qu, W., Wang, W., Lu, Y., Wu, Y., Li, Z., Hang, X., Wang, X., Zhao, D., and Zhang, C. (2010). MPprimer: a program for reliable multiplex PCR primer design. *BMC bioinformatics* 11, 143.

Shih, C., Padhy, L.C., Murray, M., and Weinberg, R.A. (1981). Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature* 290, 261-264.

Shlien, A., Campbell, B.B., de Borja, R., Alexandrov, L.B., Merico, D., Wedge, D., Van Loo, P., Tarpey, P.S., Coupland, P., Behjati, S., *et al.* (2015). Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. *Nature genetics* 47, 257-262.

Shlush, L.I., Mitchell, A., Heisler, L., Abelson, S., Ng, S.W.K., Trotman-Grant, A., Medeiros, J.J.F., Rao-Bhatia, A., Jaciw-Zurakowsky, I., Marke, R., *et al.* (2017). Tracing the origins of relapse in acute myeloid leukaemia to stem cells. *Nature* 547, 104-108.

- Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., *et al.* (2014). Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. *Nature* *506*, 328-333.
- Simon, N., Friedman, J., Hastie, T., and Tibshirani, R. (2011). Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. *J Stat Softw* *39*, 1-13.
- Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005). ROCr: visualizing classifier performance in R. *Bioinformatics (Oxford, England)* *21*, 3940-3941.
- Smith, A.L., Alirezaie, N., Connor, A., Chan-Seng-Yue, M., Grant, R., Selander, I., Bascunana, C., Borgida, A., Hall, A., Whelan, T., *et al.* (2016). Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. *Cancer letters* *370*, 302-312.
- Smith, M.L., Cavenagh, J.D., Lister, T.A., and Fitzgibbon, J. (2004). Mutation of CEBPA in familial acute myeloid leukemia. *The New England journal of medicine* *351*, 2403-2407.
- Smith, S.M., Le Beau, M.M., Huo, D., Karrison, T., Sobecks, R.M., Anastasi, J., Vardiman, J.W., Rowley, J.D., and Larson, R.A. (2003). Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. *Blood* *102*, 43-52.
- Sondka, Z., Bamford, S., Cole, C.G., Ward, S.A., Dunham, I., and Forbes, S.A. (2018). The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. *Nature reviews Cancer* *18*, 696-705.
- Sperling, A.S., Gibson, C.J., and Ebert, B.L. (2017). The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. *Nature reviews Cancer* *17*, 5-19.
- Stanley, N., Olson, T.S., and Babushok, D.V. (2017). Recent advances in understanding clonal haematopoiesis in aplastic anaemia. *British journal of haematology* *177*, 509-525.
- Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A., Hasserjian, R.P., and Ebert, B.L. (2015). Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood* *126*, 9-16.
- Stein, E.M. (2015). Molecularly targeted therapies for acute myeloid leukemia. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program* *2015*, 579-583.
- Stenson, P.D., Ball, E.V., Mort, M., Phillips, A.D., Shiel, J.A., Thomas, N.S., Abeyasinghe, S., Krawczak, M., and Cooper, D.N. (2003). Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat* *21*, 577-581.
- Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., Pleasance, E.D., Lau, K.W., Beare, D., Stebbings, L.A., *et al.* (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* *144*, 27-40.

Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., *et al.* (2012). The landscape of cancer genes and mutational processes in breast cancer. *Nature* *486*, 400-404.

Storr, S.J., Safuan, S., Ahmad, N., El-Refae, M., Jackson, A.M., and Martin, S.G. (2017). Macrophage-derived interleukin-1 β promotes human breast cancer cell migration and lymphatic adhesion in vitro. *Cancer immunology, immunotherapy* : *CII* *66*, 1287-1294.

Strati, P., and Shanafelt, T.D. (2015). Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. *Blood* *126*, 454-462.

Stratton, M.R. (2011). Exploring the genomes of cancer cells: progress and promise. *Science (New York, NY)* *331*, 1553-1558.

Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009). The cancer genome. *Nature* *458*, 719-724.

Stutzman-Engwall, K.J., and Hutchinson, C.R. (1989). Multigene families for anthracycline antibiotic production in *Streptomyces peucetius*. *Proceedings of the National Academy of Sciences of the United States of America* *86*, 3135-3139.

Suda, K., Nakaoka, H., Yoshihara, K., Ishiguro, T., Tamura, R., Mori, Y., Yamawaki, K., Adachi, S., Takahashi, T., Kase, H., *et al.* (2018). Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium. *Cell reports* *24*, 1777-1789.

Sun, R., Hu, Z., Sottoriva, A., Graham, T.A., Harpak, A., Ma, Z., Fischer, J.M., Shibata, D., and Curtis, C. (2017). Between-region genetic divergence reflects the mode and tempo of tumor evolution. *Nature genetics* *49*, 1015-1024.

Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D., *et al.* (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* *127*, 2375-2390.

Tabin, C.J., Bradley, S.M., Bargmann, C.I., Weinberg, R.A., Papageorge, A.G., Scolnick, E.M., Dhar, R., Lowy, D.R., and Chang, E.H. (1982). Mechanism of activation of a human oncogene. *Nature* *300*, 143-149.

Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., *et al.* (2017). Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. *The Lancet Oncology* *18*, 100-111.

Tartaglia, M., Niemeyer, C.M., Fragale, A., Song, X., Buechner, J., Jung, A., Hahlen, K., Hasle, H., Licht, J.D., and Gelb, B.D. (2003). Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. *Nature genetics* *34*, 148-150.

Tate, J.G., Bamford, S., Jubb, H.C., Sondka, Z., Beare, D.M., Bindal, N., Boutselakis, H., Cole, C.G., Creatore, C., Dawson, E., *et al.* (2019). COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic acids research* *47*, D941-D947.

TCGA, Ley, T.J., Miller, C., Ding, L., Raphael, B.J., Mungall, A.J., Robertson, A., Hoadley, K., Triche, T.J., Jr., Laird, P.W., *et al.* (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *The New England journal of medicine* *368*, 2059-2074.

Therneau, T., and Grambsch, P.M. (2000). *Modeling Survival Data: Extending the Cox Model*, 1st edn edn (New York: Springer-Verlag).

Thompson, D., Genovese, G., Halvardson, J., Ulirsch, J., Wright, D., Terao, C., Davidsson, O., Day, F., Sulem, P., Jiang, Y., *et al.* (2019). Genetic predisposition to mosaic Y chromosome loss in blood is associated with genomic instability in other tissues and susceptibility to non-haematological cancers. 514026.

Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M.P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V.A., *et al.* (2011). BRAF mutations in hairy-cell leukemia. *The New England journal of medicine* *364*, 2305-2315.

Turcotte, L.M., Neglia, J.P., Reulen, R.C., Ronckers, C.M., van Leeuwen, F.E., Morton, L.M., Hodgson, D.C., Yasui, Y., Oeffinger, K.C., and Henderson, T.O. (2018). Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* *36*, 2145-2152.

Tyner, J.W., Tognon, C.E., Bottomly, D., Wilmot, B., Kurtz, S.E., Savage, S.L., Long, N., Schultz, A.R., Traer, E., Abel, M., *et al.* (2018). Functional genomic landscape of acute myeloid leukaemia. *Nature* *562*, 526-531.

Uno, H., Cai, T., Tian, L., and Wei, L.J. (2007). Evaluating Prediction Rules for t-Year Survivors With Censored Regression Models. *Journal of the American Statistical Association* *102*, 527-537.

Van den Neste, E., Andre, M., Gastinne, T., Stamatoullas, A., Haioun, C., Belhabri, A., Reman, O., Casasnovas, O., Guesquieres, H., Verhoef, G., *et al.* (2018). Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. *Haematologica*.

Van Loo, P., Nordgard, S.H., Lingjaerde, O.C., Russnes, H.G., Rye, I.H., Sun, W., Weigman, V.J., Marynen, P., Zetterberg, A., Naume, B., *et al.* (2010). Allele-specific copy number analysis of tumors. *Proceedings of the National Academy of Sciences of the United States of America* *107*, 16910-16915.

Van Vlierberghe, P., and Ferrando, A. (2012). The molecular basis of T cell acute lymphoblastic leukemia. *The Journal of clinical investigation* *122*, 3398-3406.

Vannucchi, A.M., and Harrison, C. (2016). Emerging treatments for classical myeloproliferative neoplasms. *Blood*.

- Vattathil, S., and Scheet, P. (2016). Extensive Hidden Genomic Mosaicism Revealed in Normal Tissue. *American journal of human genetics* 98, 571-578.
- Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., *et al.* (2001). The sequence of the human genome. *Science (New York, NY)* 291, 1304-1351.
- Vickers, A.J. (2011). Prediction models in cancer care. *CA: a cancer journal for clinicians* 61, 315-326.
- Vitols, S., Angelin, B., Ericsson, S., Gahrton, G., Juliusson, G., Masquelier, M., Paul, C., Peterson, C., Rudling, M., Soderberg-Reid, K., *et al.* (1990). Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America* 87, 2598-2602.
- Vitols, S., Gahrton, G., Bjorkholm, M., and Peterson, C. (1985). Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. *Lancet (London, England)* 2, 1150-1154.
- Vitols, S., Gahrton, G., Ost, A., and Peterson, C. (1984). Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. *Blood* 63, 1186-1193.
- Vitols, S., Peterson, C., Larsson, O., Holm, P., and Aberg, B. (1992). Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. *Cancer research* 52, 6244-6247.
- Voso, M.T., Fabiani, E., Zang, Z., Fianchi, L., Falconi, G., Padella, A., Martini, M., Li Zhang, S., Santangelo, R., Larocca, L.M., *et al.* (2015). Fanconi anemia gene variants in therapy-related myeloid neoplasms. *Blood cancer journal* 5, e323.
- Wander, S.A., Levis, M.J., and Fathi, A.T. (2014). The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. *Therapeutic advances in hematology* 5, 65-77.
- Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S.S., *et al.* (2018). Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2 α . *Nature communications* 9, 559.
- Wang, X., Oldani, M.J., Zhao, X., Huang, X., and Qian, D. (2014). A review of cancer risk prediction models with genetic variants. *Cancer informatics* 13, 19-28.
- Waterman, J., Rybicki, L., Bolwell, B., Copelan, E., Pohlman, B., Sweetenham, J., Dean, R., Sobecks, R., Andresen, S., and Kalaycio, M. (2012). Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. *Bone Marrow Transplant* 47, 488-493.
- Wegert, J., Vokuhl, C., Collord, G., Del Castillo Velasco-Herrera, M., Farndon, S.J., Guzzo, C., Jorgensen, M., Anderson, J., Slater, O., Duncan, C., *et al.* (2018). Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. *Nature communications* 9, 2378.

Welch, J.S. (2014). Mutation position within evolutionary subclonal architecture in AML. *Seminars in hematology* 51, 273-281.

Welch, J.S., Ley, T.J., Link, D.C., Miller, C.A., Larson, D.E., Koboldt, D.C., Wartman, L.D., Lamprecht, T.L., Liu, F., Xia, J., *et al.* (2012). The origin and evolution of mutations in acute myeloid leukemia. *Cell* 150, 264-278.

Wolach, O., Sellar, R.S., Martinod, K., Cherpokova, D., McConkey, M., Chappell, R.J., Silver, A.J., Adams, D., Castellano, C.A., Schneider, R.K., *et al.* (2018). Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. *Science translational medicine* 10.

Wong, T.N., Miller, C.A., Klco, J.M., Petti, A., Demeter, R., Helton, N.M., Li, T., Fulton, R.S., Heath, S.E., Mardis, E.R., *et al.* (2015a). Rapid expansion of pre-existing non-leukemic hematopoietic clones frequently follows induction therapy for de novo AML. *Blood*.

Wong, T.N., Ramsingh, G., Young, A.L., Miller, C.A., Touma, W., Welch, J.S., Lamprecht, T.L., Shen, D., Hundal, J., Fulton, R.S., *et al.* (2015b). Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature* 518, 552-555.

Woyach, J.A., and Johnson, A.J. (2015). Targeted therapies in CLL: mechanisms of resistance and strategies for management. *Blood* 126, 471-477.

Wright, D.J., Day, F.R., Kerrison, N.D., Zink, F., Cardona, A., Sulem, P., Thompson, D.J., Sigurjonsdottir, S., Gudbjartsson, D.F., Helgason, A., *et al.* (2017). Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility. *Nature genetics* 49, 674-679.

Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., *et al.* (2014). Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nature medicine* 20, 1472-1478.

Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R.H., Eshleman, J.R., Nowak, M.A., *et al.* (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 467, 1114-1117.

Yahata, T., Takanashi, T., Muguruma, Y., Ibrahim, A.A., Matsuzawa, H., Uno, T., Sheng, Y., Onizuka, M., Ito, M., Kato, S., *et al.* (2011). Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. *Blood* 118, 2941-2950.

Yalcin, B., Kremer, L.C., and van Dalen, E.C. (2015). High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. *The Cochrane database of systematic reviews*, Cd006301.

Yang, H., and Wang, K. (2015). Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. *Nat Protocols* 10, 1556-1566.

Yates, J.W., Wallace, H.J., Jr., Ellison, R.R., and Holland, J.F. (1973). Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. *Cancer chemotherapy reports* 57, 485-488.

Yates, L.R., and Campbell, P.J. (2012). Evolution of the cancer genome. *Nature reviews Genetics* 13, 795-806.

Ying, Z., Sandoval, M., and Beronja, S. (2018). Oncogenic activation of PI3K induces progenitor cell differentiation to suppress epidermal growth. *Nature cell biology* 20, 1256-1266.

Yizhak, K., Aguet, F., Kim, J., Hess, J., Kubler, K., Grimsby, J., Frazer, R., Zhang, H., Haradhvala, N., Rosebrock, D., *et al.* (2018). A comprehensive analysis of RNA sequences reveals macroscopic somatic clonal expansion across normal tissues. 416339.

Yokoyama, A., Kakiuchi, N., Yoshizato, T., Nannya, Y., Suzuki, H., Takeuchi, Y., Shiozawa, Y., Sato, Y., Aoki, K., Kim, S.K., *et al.* (2019). Age-related remodelling of oesophageal epithelia by mutated cancer drivers. *Nature* 565, 312-317.

Yoshizato, T., Dumitriu, B., Hosokawa, K., Makishima, H., Yoshida, K., Townsley, D., Sato-Otsubo, A., Sato, Y., Liu, D., Suzuki, H., *et al.* (2015). Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. *The New England journal of medicine* 373, 35-47.

Young, A.L., Challen, G.A., Birman, B.M., and Druley, T.E. (2016). Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. *Nature communications* 7, 12484.

Zahn, L.M. (2016). Unleashing the power of precision medicine. *Science (New York, NY)* 354, 1546-1548.

Zapata, L., Pich, O., Serrano, L., Kondrashov, F.A., Ossowski, S., and Schaefer, M.H. (2018). Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. *Genome biology* 19, 67.

Zech, L., Haglund, U., Nilsson, K., and Klein, G. (1976). Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. *International journal of cancer Journal international du cancer* 17, 47-56.

Zhang, J., Walsh, M.F., Wu, G., Edmonson, M.N., Gruber, T.A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D.A., *et al.* (2015). Germline Mutations in Predisposition Genes in Pediatric Cancer. *The New England journal of medicine* 373, 2336-2346.

Zhou, J., Li, Y.S., Wang, K.C., and Chien, S. (2014). Epigenetic Mechanism in Regulation of Endothelial Function by Disturbed Flow: Induction of DNA Hypermethylation by DNMT1. *Cellular and molecular bioengineering* 7, 218-224.

Zhou, W., Machiela, M.J., Freedman, N.D., Rothman, N., Malats, N., Dagnall, C., Caporaso, N., Teras, L.T., Gaudet, M.M., Gapstur, S.M., *et al.* (2016). Mosaic loss of chromosome Y is associated with common variation near TCL1A. *Nature genetics* 48, 563-568.

Zhu, L., Finkelstein, D., Gao, C., Shi, L., Wang, Y., Lopez-Terrada, D., Wang, K., Utley, S., Pounds, S., Neale, G., *et al.* (2016). Multi-organ Mapping of Cancer Risk. *Cell* *166*, 1132-1146.e1137.

Zink, F., Stacey, S.N., Norddahl, G.L., Frigge, M.L., Magnusson, O.T., Jonsdottir, I., Thorgeirsson, T.E., Sigurdsson, A., Gudjonsson, S.A., Gudmundsson, J., *et al.* (2017). Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. *Blood* *130*, 742-752.

Zong, C., Lu, S., Chapman, A.R., and Xie, X.S. (2012). Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. *Science (New York, NY)* *338*, 1622-1626.

Zuna, J., Madzo, J., Krejci, O., Zemanova, Z., Kalinova, M., Muzikova, K., Zapotocky, M., Starkova, J., Hrusak, O., Horak, J., *et al.* (2011). ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia. *Blood* *117*, 368-369; author reply 370-361.